Jean Eduardo Meneguello

Jean Eduardo Meneguello

Auto-generated profile, based on publicly available information

Jean Eduardo Meneguello

Graduate Program in Biosciences and Physiopathology, State University Maringá, Maringá, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JMJean Eduardo Meneguello
Jean Eduardo Meneguello
LMLetícia Sayuri Murase
Letícia Sayuri Murase
JSJoão Vitor Perez de Souza
João Vitor Perez de Souza
COCheila Guimarães de Oliveira
Cheila Guimarães de Oliveira
LGLuciana Dias Ghiraldi-Lopes
Luciana Dias Ghiraldi-Lopes
RCRosilene Cardoso
Rosilene Cardoso

3 October 2024 in Future Microbiology
Verified
Journal Article
Closed access
AIAndressa Lorena Ieque
Andressa Lorena Ieque
CPCarolina Trevisolli Palomo
Carolina Trevisolli Palomo
DMDeborah de Castro Moreira
Deborah de Castro Moreira
JMJean Eduardo Meneguello
Jean Eduardo Meneguello
LMLetícia Sayuri Murase
Letícia Sayuri Murase
RSRegiane Bertin De Lima Scodro
Regiane Bertin De Lima Scodro
Aim: Tuberculous meningitis (TBM) is one of the most severe clinical forms of tuberculosis (TB). Since epidemiological studies can contribute to TB control, we conducted a review and meta-analysis of epidemiological publications of adults TBM cases in countries with high incidence of TB.Materials & methods: The search resulted in 11,855 articles, in which 21 ultimately were included in our review and 15 in our meta-analysis.Results: TBM mortality was 25% with death rates of 70% in Africa. The review showed different and non-concordant diagnostic techniques and treatment schemes.Conclusion: Adults living in the African region are at high risk of death from TBM, highlighting an urgent need of guidelines to support diagnosis and treatment, and ultimately, to reduce mortality.

26 October 2023 in Future Microbiology
Verified
Journal Article
Closed access
LMLetícia Sayuri Murase
Letícia Sayuri Murase
JSJoão Vítor Perez de Souza
João Vítor Perez de Souza
JMJean Eduardo Meneguello
Jean Eduardo Meneguello
CPCarolina Trevisolli Palomo
Carolina Trevisolli Palomo
ÁRÁquila Carolina Fernandes Herculano Ramos-Milaré
Áquila Carolina Fernandes Herculano Ramos-Milaré
RCRosilene Cardoso
Rosilene Cardoso
Aim: To review in vitro, in vivo, and in silico studies examining the antibacterial and immunomodulatory properties of piperine (PPN). Methods: This systematic review followed PRISMA guidelines, an... Graphical abstract

30 September 2021 in Future Microbiology
Verified
Journal Article
Closed access
PQPaula A Queiroz
Paula A Queiroz
JMJean E Meneguello
Jean E Meneguello
BSBruna R Silva
Bruna R Silva
KCKatiany R Caleffi-Ferracioli
Katiany R Caleffi-Ferracioli
RSRegiane Bl Scodro
Regiane Bl Scodro
VSVera Ld Siqueira
Vera Ld Siqueira
Aim: To elucidate the changes in protein expression associated with polymyxin resistance in Klebsiella pneumoniae, we profiled a comparative proteomic analysis of polymyxin B-resistant mutants KPC-...

30 April 2025 in Microbial Drug Resistance
Verified
Journal Article
Closed access
ANAndressa Araújo Machado Do Nascimento
Andressa Araújo Machado Do Nascimento
CPCarolina Trevisolli Palomo
Carolina Trevisolli Palomo
RSRegiane Bertin de Lima Scodro
Regiane Bertin de Lima Scodro
KCKatiany Rizzieri Caleffi-Ferracioli
Katiany Rizzieri Caleffi-Ferracioli
VSVera Lucia Dias Siqueira
Vera Lucia Dias Siqueira
RCRosilene Fressatti Cardoso
Rosilene Fressatti Cardoso
Rapidly growing mycobacteria (RGM) have been causing diseases with an increasing incidence that require long and difficult treatment. In this regard, it is a priority to seek rapid and low-cost optimization of therapeutic alternatives. Thus, our objective is to explore the combined activity between verapamil (VP) and the antimicrobials clarithromycin, amikacin, and clofazimine (CFZ) against Mycobacterium smegmatis , Mycobacterium abscessus subsp. abscessus , Mycobacterium abscessus subsp. massiliense , Mycobacterium abscessus subsp. bolletii , Mycobacterium chelonae , and Mycobacterium fortuitum . According to the checkerboard assay, it was observed that the best combination was between VP and CFZ, with synergistic activity on all tested bacteria. The time-killing assay demonstrated that VP improved the killing of CFZ and extended its inhibitory activity 16 times. In this sense, VP has modulating activity with most of the tested antimicrobials, especially with CFZ, and thus may have potential activity in preventing bacterial resistance that could be pointed out as a model for synergism in attempts at screening molecules for RGM infection treatments.

1 January 2022 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
BFBeatriz Cardoso de Freitas
Beatriz Cardoso de Freitas
JMJean Eduardo Meneguello
Jean Eduardo Meneguello
LELivia Gisella Fernandes Eugenio
Livia Gisella Fernandes Eugenio
RLRhayana Lemos
Rhayana Lemos
RSRegiane Bertin de Lima Scodro
Regiane Bertin de Lima Scodro
RCRosilene Cardoso
Rosilene Cardoso